159 related articles for article (PubMed ID: 10950366)
1. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.
Swinnen LJ
Semin Oncol; 2000 Aug; 27(4):402-8. PubMed ID: 10950366
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies.
Swinnen LJ
J Natl Cancer Inst Monogr; 2001; (28):38-43. PubMed ID: 11158205
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV.
Ibrahim HA; Menasce LP; Pomplun S; Burke M; Bower M; Naresh KN
Eur J Haematol; 2010 Sep; 85(3):227-30. PubMed ID: 20408873
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
Taylor AL; Marcus R; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
[TBL] [Abstract][Full Text] [Related]
5. Immunodeficiency-associated lymphoproliferative disorders.
Knowles DM
Mod Pathol; 1999 Feb; 12(2):200-17. PubMed ID: 10071343
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
7. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
8. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
11. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
12. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant lymphoproliferative disorder: a review.
Loren AW; Porter DL; Stadtmauer EA; Tsai DE
Bone Marrow Transplant; 2003 Feb; 31(3):145-55. PubMed ID: 12621474
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
Markasz L; Stuber G; Flaberg E; Jernberg AG; Eksborg S; Olah E; Skribek H; Szekely L
BMC Cancer; 2006 Nov; 6():265. PubMed ID: 17101045
[TBL] [Abstract][Full Text] [Related]
15. Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.
Murray PG; Swinnen LJ; Flavell JR; Ragni MV; Baumforth KR; Toomey SM; Filipovich AH; Lowe D; Schnell CS; Johl J; Gulley M; Young LS; Ambinder RF
Hum Pathol; 2001 Sep; 32(9):963-9. PubMed ID: 11567226
[TBL] [Abstract][Full Text] [Related]
16. Treatment for Epstein-Barr virus-associated PTLD.
Gross TG
Herpes; 2009 Jan; 15(3):64-7. PubMed ID: 19306606
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
Capello D; Berra E; Cerri M; Gaidano G
Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
[TBL] [Abstract][Full Text] [Related]
18. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
[TBL] [Abstract][Full Text] [Related]
19. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
20. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]